Explore the neuroimmune story behind AD

A chronic and flaring skin condition leading to intense scratching, driven by both inflammatory and neuronal mechanisms1,2

Atopic dermatitis is the most common form of eczema, characterized by persistent itch, inflammation, lesions, skin barrier dysfunction, and fibrosis3

Intense itch is the most burdensome symptom for patients living with AD2

of patients seek freedom 
from itch4

are not fully satisfied with 
current treatments4

Complex neuroimmune interactions contribute to the pathophysiology of AD1

Inflammatory responses in the skin amplify the stimulation of sensory nerves in the dermal layer, leading to the intractable and debilitating itch experienced by patients with atopic dermatitis1

Neuronal mechanisms

Signaling between cutaneous nerve fibers in the skin to the dorsal root ganglia, spinal cord, and brain amplifies the relentless and intractable itch sensation1

IMMUNE mechanisms

The release of inflammatory cytokines into the skin contributes to inflammation and leads to skin barrier disruption and impaired keratinocyte differentiation, intensifying itch, and fibrosis1

When both the neuronal and immune aspects of atopic dermatitis aren’t addressed directly, some patients may continue to suffer1

The role of IL-31 in itch and more1

IL-31 has emerged as a key neuroimmune cytokine and a direct driver of:

  • ITCH
  • INFLAMMATION
  • SKIN BARRIER DYSFUNCTION
  • FIBROSIS

Lasting Skin Healing5

Discover how NEMLUVIO helped most patients with AD achieve lasting skin clearance5

SEE THE DIFFERENCE 

Unique Mechanism of Action1,6

NEMLUVIO is the first treatment to target IL-31RA, a key neuroimmune driver of itch and more in PN and AD1,6

LEARN MORE 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.